Jivolar

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jivolar, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower elevated blood glucose levels when used in combination with diet and exercise.

GNH USA supplies Jivolar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for chronic disease management and supporting patient care programs.

Jivolar combines metformin and sitagliptin to address hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus (initial therapy): lowers fasting and post‑prandial glucose levels as part of a comprehensive treatment plan. - Type 2 diabetes mellitus (add‑on therapy): enhances glycaemic control when metformin alone is insufficient. - Type 2 diabetes mellitus (metformin intolerance): provides glucose reduction via DPP‑4 inhibition for patients who cannot tolerate metformin.

Jivolar may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycaemia: especially when combined with insulin or sulfonylureas. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication. - Severe hypoglycaemia: prolonged low blood glucose requiring medical intervention. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Allergic reactions: rash, itching, or angioedema. - Hepatic dysfunction: abnormal liver enzyme elevations. - Renal impairment: worsening kidney function in susceptible individuals.

Before prescribing Jivolar, clinicians should evaluate patient-specific risk factors and monitor relevant parameters.

- Renal function: assess eGFR before initiating and periodically monitor kidney performance. - Hepatic function: use with caution in patients with existing liver disease. - Lactic acidosis risk: avoid in conditions predisposing to hypoxia such as severe heart failure or respiratory compromise. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Drug interactions: review concomitant medications for possible pharmacodynamic or pharmacokinetic conflicts. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Jivolar can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to lactic acidosis risk. - Co‑administration with other DPP‑4 inhibitors: duplicate therapy should be avoided. - Potent CYP2C8 inhibitors: may increase metformin plasma concentrations. - Combined use with insulin or sulfonylureas: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Alcohol intake: may potentiate metformin‑associated lactic acidosis. - Iodinated contrast media: temporary discontinuation of metformin is recommended. - Beta‑blockers: can mask symptoms of hypoglycaemia, requiring closer glucose monitoring.